Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Center for Ophthalmic and Vision Research, LLC
Collaborators
NCT01425892 · Sjogren's Syndrome, Salivary Gland, and more
NCT07526350 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, and more
NCT07463950 · Dry Eye Disease (DED)
NCT07413341 · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), and more
NCT07412860 · Dry Eye Syndromes, Dry Eye Disease (DED)
Center for Ophthalmic and Vision Recearch
Manhattan, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions